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Abstract 
Background and Aim: Acetaminophen (APAP) is a commonly used analgesic and also the leading cause of 
medication-induced liver damage. On the other hand, N-acetylcysteine (NAC) is a medication widely used to 
treat APAP overdose. Despite this interest, a few studies have investigated the co-administration effects of these 
medications. Therefore, this study aimed to evaluate the effects of NAC and APAP on renal and liver functions 
in rats when they use concurrently. 
Methods: Male Wistar rats were orally treated with a single dose of APAP (700 mg/kg) alone or in combination 
of NAC at the three different doses (200, 500, and 700 mg/kg). After 24 hours, the blood and liver samples were 
collected for biochemical and histopathological evaluations. 
Results: Liver damage was well established in the 700 mg/kg APAP-treated rats, as evidenced by elevated the 
plasma levels of aspartate transaminase (AST) and alanine transaminase (ALT). In addition, the plasma level of 
blood urea nitrogen (BUN) was significantly increased in the APPA group compared to the control group.   
Moreover, histological examinations revealed that liver degeneration was evident in APAP-treated animals. 
NAC only at the highest dose (700 mg/kg) could inhibit ALT elevation, but had no effect on AST and BUN 
levels. Interestingly, co-administration of NAC (700 mg/kg) with APAP (700 mg/kg) could slightly shift liver 
histological alterations from the irreversible stage (fibrosis) toward reversible lesions such as necrosis and 
hemorrhage. 
Conclusion: The study findings indicate that co-administration of NAC and APAP can reduce the severity of 
APAP-induced liver damage in rats. 
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Paracetamol, also known as acetaminophen or 
APAP, is widely used to treat pain and fever. Even 
though APAP is generally safe at recommended 
doses, its overdose can cause liver toxicity (1). 
APAP liver toxicity is among the most commonly 
occurring poisonings worldwide (2). N-
acetylcysteine (NAC) was first proposed in 1970 as 
an effective antidote for APAP poisoning, inhibiting 
the binding of N-acetyl-P-benzoquinone (NAPQI) to 
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liver cells (3). NAC is a well-known and readily 
available antidote for the treatment of APAP-
induced toxicity. It also has antioxidant and anti-
inflammatory properties (4, 5). NAC is not only 
prescribed as an antidote for APAP toxicity, but also 
it is effective in eliminating the toxicity of heavy 
metals such as lead (6).  Moreover, it is administered 
in internal medicine to treat idiopathic lung fibrosis 
and as an agent with antimicrobial and vasodilator 
effects (7-9). It is used to prevent contrast-induced 
nephropathy and prevent possible hearing loss 
following gentamicin use, especially in children and 
infants (10). Despite the widespread use of high 
doses of NAC, no toxicity has yet been reported. 
Evidence demonstrated that the golden time for NAC 
consumption as an antidote after APAP overdose is 
8-hour (11). 
In 2011, Mehrpour et al. suggested that a drug can be 
produced by mixing of APAP and NAC in order to 
prevent the toxic effects of APAP(12). Subsequently, 
some studies have examined the concomitant effect 
of the two drugs (13). We recently found that co-
administration of NAC with APAP can improve the 
antinociceptive effect of APAP(14). Therefore, we 
are aiming to formulate a new pharmaceutical drug, 
acetaminophen tablet containing NAC. So, in the 
first step, we designed this animal study to evaluate 
the efficacy of this combination on the severity of 
liver and kidney damage in rats. 
Methods 
Animals and study design 
The protocol of this study was based on the 
international rules of handling laboratory animals 
approved by the Ethics Committee of Birjand 
University of Medical Sciences (Permit code: 
IR.bums.REC.1395.296).  
48 male Wistar rats weighing 200 ± 20 g were 
obtained from the animal facility of Research Centre 
of Experimental Medicine, Birjand University of 
Medical Sciences. The animals were kept in 
propylene cages, temperature-controlled room 
(22±2º C) with a 12-h light/dark cycle. The animals 
had free access to the standard laboratory animal diet 
(Behparvar, Iran) and tap water during the study 
period. The rats were randomly assigned into six 
equal groups (n= 8, each). Before starting 
investigations, the rats were kept on fast for 12-h but 
had free access to water. 
Experimental protocol 
The rats were randomly divided into six equal groups 
(n=8, each) and treated as follows: 
• Group I (control): This group only received 
saline; 
• Group II (NAC): This group was treated with 
700 mg/kg NAC dissolved in saline; 
• Group III (APAP): Treated with 700 mg/kg 
APAP dissolved in saline as a model group; 
• Group IV (APAP+NAC200): Concurrently 
treated with 700 mg/kg APAP and 200 mg/kg 
NAC; 
• Group V (APAP+NAC500): Concurrently 
treated with 700 mg/kg APAP and 500 mg/kg 
NAC; 
• Group VI (APAP+NAC700): Concurrently 
treated with 700 mg/kg APAP and 700 mg/kg 
NAC. 
All the treatments were done orally in equal volume 
(1mL) using a gastric tube. After 24 hours of the 
investigations, the animals were anesthetized using 
intraperitoneal injection of ketamine and xylazine 
(75:10 mg/kg) (15). Afterward, the blood samples 
were collected from the heart, and serum was 
separated by centrifugation at 2500 g for 10 minutes.  
The biochemical parameters, including blood urea 
nitrogen (BUN), creatinine (Cr), aspartate 
transaminase (AST), and alanine transaminase 
(ALT), were evaluated using standard diagnostic kits 
(Bionick, Iran).  
Following the blood collection, the liver of each 
animal was immediately dissected out, weighed, and 
placed in 10% formalin. After 48 hours, the liver 
samples were processed for paraffin embedding. 
Sections of 5 thick were cut, deparaffinized in 
xylene, rehydrated in serial graded ethanol solutions, 
and then used for Masson's Trichrome Staining to 
evaluate liver damage. 
Statistical analysis 
Data analysis was performed using SPSS19 
software. Shapiro-Wilk test was used to evaluate the 
data homogeneity. ANOVA test was employed in 
case of the normal distribution; otherwise, the 
Kruskal-Wallis test was applied. Tukey post hoc test 
Formulating a New Pharmaceutical Drug; Acetaminophen Tablet Containing…                                 Mehrpour O, et al. 
Archives of Medical Laboratory Sciences; Volume 7, 2021 (Continuous Volume)  3 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License 
was used to compare each pair of groups. P values 
≤0.5 were considered significant. 
Results 
Biochemical parameters 
The results of serum concentrations of liver enzymes 
(AST, ALT) and kidney function markers (BUN, Cr) 
were presented in Table 1. Accordingly, Both liver 
enzymes and BUN levels were significantly elevated 
in APAP-treated group in comparison with the 
control (p < 0.01, each). Co-administration of APAP 
with NAC in all doses could not ameliorate AST 
elevation in rats. However, NAC-treated rats 
exhibited a significant decrease only in ALT level 
compared to the APAP-poisoned group. In other 
words, ALT level of the APAP+NAC700 group was 
significantly lower than APAP-poisoned group (p < 
0.05).  
Co-administration of NAC with APAP at all doses 
could not mitigate BUN increasing in APAP-treated 
rats. Despite the fact that Cr levels in the APAP-
poisoned animals tended to increase, but the change 
was not statistically significant in comparison with 
control group (p = 0.051). 
Macroscopic change of livers 
Figure 1 shows the results of the liver-to-body 
weight ratio in the studied groups. Compared to the 
control group, the mean liver-to-body ratios of the 
APAP, APAP+200 mg/kg NAC, APAP+500 mg/kg 
NAC, and APAP+700 mg/kg NAC were 
significantly decreased (p <0.05). None of the 
treatments could prevent this reduction in the 
animals. 
Histological evaluation 
Histological examination of the liver sections of 
normal and experimentally treated animals was 
presented in Figures 2 and 3. The liver tissues belong 
to the control group exhibited normal appearance 
without any significant inflammation, sinusoidal 
hemorrhage or dilatation, and hepatocytes 
degeneration. Similarly, NAC-treated normal rats 
showed normal liver architecture without any 
evident degeneration, inflammation, or hemorrhage 
(Figure 2). 
On the other hand, the liver sections of APAP-treated 
animals exhibited severe liver damage, which 
represents diffuse fibrotic lesions between 
hepatocytes, portal space, lobular central vein, and 
even sinusoids (Figure 3). Moreover, other 
histological changes such as infiltration and 
sinusoidal hemorrhage were evident in this group. 
Histological examination of APAP-treated rats 
which were concurrently treated with NAC at the 
doses of 200 and 500 mg, revealed pathological 
appearance as same as APAP group. However, at the 
dose of 700 mg/kg, NAC could mitigate APAP 
histological damages from irreversible changes such 
as fibrosis to reversible changes like necrosis (Figure 
3). 
In the present study, concurrent administration of 
NAC with a toxic dose of APAP (700 mg/kg) was 
investigated to determine whether NAC could 
prevent APAP poisoning. Accordingly, biochemical 
parameters regarding liver function, including AST 
and ALT and kidney function markers such as BUN 
and Cr, were evaluated. Furthermore, liver histology 
was performed to assess the severity of APAP-
induced hepatic injury in rats. This study clearly 
demonstrated that APAP (700 mg/kg) induced liver 
toxicity and renal damage by increasing liver 
enzymes activity and elevating BUN levels, 
respectively. Histological examination of liver 
tissues showed that APAP induced severe and 
irreversible pathological alterations, mainly collagen 
diffusion and fibrosis.  
NAC at the highest dose could significantly prevent 
ALT elevation in rats. None of the NAC doses could 
ameliorate the elevations of AST and BUN levels 
and also improve liver-to-body weight ratio in 
APAP-poisoned rats. It worth be noted that 24 hours 
after APAP poisoning, all of the rats in the model 
group (APAP 700 mg/kg) were lethargic and 
sedentary, while those receiving NAC demonstrated 
normal behavior, suggesting an effect of NAC 
against APAP toxicity.  
Based on the current protocols, NAC is 
recommended as a known antidote to control the 
toxic effects of APAP. The FDA-approved dosage 
regimen for oral NAC starts with a loading dose of 
140 mg/kg followed by 17 doses, each at 70 mg/kg, 
given every 4 hours. An important factor in 
evaluating the effectiveness of NAC is the timing, 
and it is practically ineffective if it is taken after 10 
hours from APAP overdose (16). Several studies 
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indicate that NAC consumed within 8 hours from 
APAP overdose can inhibit its toxic effects (11).  
As stated earlier in this paper, in 2011, Mehrpour et 
al. hypothesized that a drug composed of APAP and 
NAC be produced to prevent the toxic effects of 
APAP (12). In 2015, Owumi et al. tested this 
hypothesis on an animal model. The results of their 
study indicated that oral co-administration of these 
two drugs positively prevented APAP poisoning 
(13). In 2017, Mast et al. treated rats with foods 
containing 1% APAP and 0.5% NAC for two weeks, 
which effectively reduced ALT levels and inhibited 
weight loss (17). Another pharmacological issue of 
formulating a combination of APAP and NAC is its 
efficacy. Therefore, our team carried out an 
experimental study in which the antinociceptive 
activity of APAP+NAC formulation has been 
investigated. We found that co-administration of 
NAC with APAP can improve the antinociceptive 
effect of APAP (14).  
The liver is the main body organ in the metabolism 
and detoxification of drugs and is prone to be harmed 
by a large number of medicinal and environmental 
chemicals. Regardless of its cause, liver damage 
occurs with five general types of responses 
(inflammation, degeneration, necrosis and apoptosis, 
fibrosis, and cirrhosis) (18). Our results revealed that 
NAC in a dose dependent manner inhibited 
pathological alterations in the liver tissue of APAP-
poisoned rats. NAC could prevent liver fibrosis, as 
the sign of the last stage of liver damage, although 
there were still some complications such as necrosis, 
hemorrhage, and dilation of the sinusoid space.   
Liver cell necrosis is also one of the most common 
responses of the liver to toxins so that in the case of 
severe coagulation necrosis, liver cells get weakly 
stained and become mummified, and their nuclei are 
often destructed. In our study, the poisoned group 
received a dose of 700 mg/kg of NAC, and more 
mildly, the group APAP+NAC 500 showed necrosis 
of liver cells, especially in the space around the 
lobular central vein, indicating ischemic injury due 
to toxic reactions to drugs. Although liver cell 
necrosis can precede inflammation, the reverse can 
also occur (19). Inflammation after the onset of 
mononuclear cells' exposure to liver cells is one of 
the common causes of liver degeneration, which was 
not observed in this study. The fibrous tissue is 
generally formed in response to swelling or direct 
damage to the liver. Unlike all previous responses 
that are reversible, fibrosis (similar to the case 
observed in the poisoned group, NAC doses of 200 
and 500 mg/kg) is generally considered to be an 
irreversible complication of liver damage. Collagen 
deposition causes a change in liver parenchymal 
hematuria. At the initial stages, fibrosis can occur 
around the portal tracts and the lobular central vein 
(similar to our findings) or directly in the space of 
Disse (as in the APAP group). As the fibrosis 
continues, nodules from regenerating liver cells are 
formed, a state that is known as cirrhosis (long-term 
effects not studied in our study) (19). According to 
the findings of this study, NAC co-administration 
with APAP could effectively modify the liver tissue 
damage from the irreversible phase (fibrosis) to 
reversible stages, such as necrosis and apoptosis. 
 
Table 1. Comparison of liver enzymes and renal function biochemical markers between the studied groups 
APAP: acetyl-para-aminophenol, NAC: N-acetylcysteine, AST: aspartate transaminase, ALT: alanine transaminase, BUN: 
blood urea nitrogen, Cr: creatinine. Values are expressed as mean ± S.D., n = 8 animals per group. * P < 0.05, ** P <0.01, 
and ***P <0.001 versus control group; # P < 0.05 versus APAP group..
Groups 
AST (IU/L) 
Mean ± SD 
ALT (IU/L) 
Mean ± SD 
BUN (mg/dl) 
Mean ± SD 
Cr (mg/dl) 
Mean ± SD 
Control 125.57±23.39 63.75±16.52 38.71 ± 4.95 0.90±0.05 
NAC 700 mg/kg 86.86±25.61 52.86±9.08 32.42 ± 6.47 0.83±0.05 
APAP (poisoned) 506.25±30.21*** 315.57±46.70*** 73.83 ± 15.95** 1.23±0.34 
APAP+200mg/kg NAC 523.83±171.10*** 318.17±112.72*** 79.0 ± 35.69** 0.95±0.33 
APAP+500mg/kg NAC 437.00±126.76*** 327.20±86.15*** 70.8 ± 6.45** 1.02±0.18 
APAP+700mg/kg NAC 564.14±79.95*** 187.57±77.19*,# 70.7 ± 19.29** 0.94±0.15 
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Figure 1. Liver index [(liver weight/body weight) × 100] in the studied groups. Values are presented as mean ± S.D, n = 8 in each 
group. APAP: acetyl-para-aminophenol, NAC: N-acetylcysteine. One way ANOVA followed Tukey's post-hoc test*p < 0.05: 
compared to control group. 
 
 
Figure 2. Histological evaluation of liver sections of normal rats treated with saline (control) or 700mg/kg of N-acetylcysteine (NAC), 
stained with Masson's Trichrome technique. 100x magnification of the liver sections showing the lobular central veins, the portal 
spaces, the normal sinusoidal radial branches, and the normal structure of the liver in both control and NAC groups. The portal space 
histology in control group indicated the presence of a small connective tissue and a very small number of mononuclear cells. Minimum 
connective tissue without any infiltration observed in the portal triad of NAC group. The lobular central vein of control and NAC 
groups indicating normal structure with normal sinusoidal space, without any signs of fibrosis. 
 
 
Figure 3. The liver sections of rats received 700 mg/kg acetyl-para-aminophenol concurrently with saline (APAP), or 200-700 mg/kg 
of N-acetylcysteine (APAP+NAC200, APAP+NAC500, and APAP+NAC700). The sections were stained with Masson's Trichrome 
technique.100x magnification indicating the wide diffusion of collagen fibers between hepatocytes and lobular central veins of all 
groups except APAP+NAC700. The portal triad space representing extensive collagen deposition in APAP group; whereas, in NAC 
treated rats the diffusion dose dependently has been moderated as far as normal in APAP+NAC700. In APAP, APAP+NAC200 and 
APAP+NAC500 groups, central vein fibrosis is evident, but normal structure with the least collagen deposition observes in 
APAP+NAC700 group. 
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Discussion 
In the present study, concurrent administration of 
NAC with a toxic dose of APAP (700 mg/kg) was 
investigated to determine whether NAC could 
prevent APAP poisoning. Accordingly, 
biochemical parameters regarding liver function, 
including AST and ALT and kidney function 
markers such as BUN and Cr, were evaluated. 
Furthermore, liver histology was performed to 
assess the severity of APAP-induced hepatic 
injury in rats. This study clearly demonstrated that 
APAP (700 mg/kg) induced liver toxicity and 
renal damage by increasing liver enzymes activity 
and elevating BUN levels, respectively. 
Histological examination of liver tissues showed 
that APAP induced severe and irreversible 
pathological alterations, mainly collagen diffusion 
and fibrosis.  
NAC at the highest dose could significantly 
prevent ALT elevation in rats. None of the NAC 
doses could ameliorate the elevations of AST and 
BUN levels and also improve liver-to-body weight 
ratio in APAP-poisoned rats. It worth be noted that 
24 hours after APAP poisoning, all of the rats in 
the model group (APAP 700 mg/kg) were 
lethargic and sedentary, while those receiving 
NAC demonstrated normal behavior, suggesting 
an effect of NAC against APAP toxicity.  
Based on the current protocols, NAC is 
recommended as a known antidote to control the 
toxic effects of APAP. The FDA-approved dosage 
regimen for oral NAC starts with a loading dose of 
140 mg/kg followed by 17 doses, each at 70 
mg/kg, given every 4 hours. An important factor 
in evaluating the effectiveness of NAC is the 
timing, and it is practically ineffective if it is taken 
after 10 hours from APAP overdose (16). Several 
studies indicate that NAC consumed within 8 
hours from APAP overdose can inhibit its toxic 
effects (11).  
As stated earlier in this paper, in 2011, Mehrpour 
et al. hypothesized that a drug composed of APAP 
and NAC be produced to prevent the toxic effects 
of APAP (12). In 2015, Owumi et al. tested this 
hypothesis on an animal model. The results of 
their study indicated that oral co-administration of 
these two drugs positively prevented APAP 
poisoning (13). In 2017, Mast et al. treated rats 
with foods containing 1% APAP and 0.5% NAC 
for two weeks, which effectively reduced ALT 
levels and inhibited weight loss(17). Another 
pharmacological issue of formulating a 
combination of APAP and NAC is its efficacy. 
Therefore, our team carried out an experimental 
study in which the antinociceptive activity of 
APAP+NAC formulation has been investigated. 
We found that co-administration of NAC with 
APAP can improve the antinociceptive effect of 
APAP (14).  
The liver is the main body organ in the metabolism 
and detoxification of drugs and is prone to be 
harmed by a large number of medicinal and 
environmental chemicals. Regardless of its cause, 
liver damage occurs with five general types of 
responses (inflammation, degeneration, necrosis 
and apoptosis, fibrosis, and cirrhosis) (18). Our 
results revealed that NAC in a dose dependent 
manner inhibited pathological alterations in the 
liver tissue of APAP-poisoned rats. NAC could 
prevent liver fibrosis, as the sign of the last stage 
of liver damage, although there were still some 
complications such as necrosis, hemorrhage, and 
dilation of the sinusoid space. 
Liver cell necrosis is also one of the most common 
responses of the liver to toxins so that in the case 
of severe coagulation necrosis, liver cells get 
weakly stained and become mummified, and their 
nuclei are often destructed. In our study, the 
poisoned group received a dose of 700 mg/kg of 
NAC, and more mildly, the group APAP+NAC 
500 showed necrosis of liver cells, especially in 
the space around the lobular central vein, 
indicating ischemic injury due to toxic reactions to 
drugs. Although liver cell necrosis can precede 
inflammation, the reverse can also occur (19). 
Inflammation after the onset of mononuclear cells' 
exposure to liver cells is one of the common 
causes of liver degeneration, which was not 
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observed in this study. The fibrous tissue is 
generally formed in response to swelling or direct 
damage to the liver. Unlike all previous responses 
that are reversible, fibrosis (similar to the case 
observed in the poisoned group, NAC doses of 200 
and 500 mg/kg) is generally considered to be an 
irreversible complication of liver damage. 
Collagen deposition causes a change in liver 
parenchymal hematuria. At the initial stages, 
fibrosis can occur around the portal tracts and the 
lobular central vein (similar to our findings) or 
directly in the space of Disse (as in the APAP 
group). As the fibrosis continues, nodules from 
regenerating liver cells are formed, a state that is 
known as cirrhosis (long-term effects not studied 
in our study) (19). According to the findings of this 
study, NAC co-administration with APAP could 
effectively modify the liver tissue damage from 
the irreversible phase (fibrosis) to reversible 
stages, such as necrosis and apoptosis. 
Conclusion 
Based on the results of this study, NAC concomitant 
use with APAP can reduce the severity of APAP-
induced liver toxicity in rats. Further clinical studies 
are needed to determine the effectiveness of NAC in 
conjunction with APAP to create a combined drug in 
individuals at risk of overdose and suicide, such as 
those with a history of psychiatric disorders 
(especially those with depression and personality 
disorders). 
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